Literature DB >> 18465252

Quality by design: concepts for ANDAs.

Robert A Lionberger1, Sau Lawrence Lee, Laiming Lee, Andre Raw, Lawrence X Yu.   

Abstract

Quality by design is an essential part of the modern approach to pharmaceutical quality. There is much confusion among pharmaceutical scientists in generic drug industry about the appropriate element and terminology of quality by design. This paper discusses quality by design for generic drugs and presents a summary of the key terminology. The elements of quality by design are examined and a consistent nomenclature for quality by design, critical quality attribute, critical process parameter, critical material attribute, and control strategy is proposed. Agreement on these key concepts will allow discussion of the application of these concepts to abbreviated new drug applications to progress.

Mesh:

Substances:

Year:  2008        PMID: 18465252      PMCID: PMC2751376          DOI: 10.1208/s12248-008-9026-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  1 in total

1.  Commentary on AAPS Workshop: dissolution testing for the twenty-first century: linking critical quality attributes and critical process parameters to clinically relevant dissolution.

Authors:  Cheng Tong; Susan S D'Souza; Jan E Parker; Tahseen Mirza
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

  1 in total
  35 in total

Review 1.  Considerations in developing a target product profile for parenteral pharmaceutical products.

Authors:  William J Lambert
Journal:  AAPS PharmSciTech       Date:  2010-09-15       Impact factor: 3.246

2.  Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers.

Authors:  Biki Gupta; Bijay Kumar Poudel; Tuan Hiep Tran; Roshan Pradhan; Hyuk-Jun Cho; Jee-Heon Jeong; Beom Soo Shin; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

Review 3.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Pharmaceutical equivalence by design for generic drugs: modified-release products.

Authors:  André Sirota Raw; Robert Lionberger; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-03-09       Impact factor: 4.200

5.  Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.

Authors:  Rong-Kun Chang; Neil Mathias; Munir A Hussain
Journal:  AAPS J       Date:  2017-07-05       Impact factor: 4.009

6.  Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength.

Authors:  Arvind Bagde; Ketan Patel; Shallu Kutlehria; Nusrat Chowdhury; Mandip Singh
Journal:  Drug Deliv Transl Res       Date:  2019-08       Impact factor: 4.617

Review 7.  Generic development of topical dermatologic products, Part II: quality by design for topical semisolid products.

Authors:  Rong-Kun Chang; Andre Raw; Robert Lionberger; Lawrence Yu
Journal:  AAPS J       Date:  2013-04-10       Impact factor: 4.009

8.  Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.

Authors:  J D Gomez-Mantilla; U F Schaefer; V G Casabo; T Lehr; C M Lehr
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

Review 9.  Understanding pharmaceutical quality by design.

Authors:  Lawrence X Yu; Gregory Amidon; Mansoor A Khan; Stephen W Hoag; James Polli; G K Raju; Janet Woodcock
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

Review 10.  Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.

Authors:  Glenn A Van Buskirk; Satish Asotra; Christopher Balducci; Prabir Basu; Gerald DiDonato; Angelica Dorantes; W Mark Eickhoff; Tapash Ghosh; Mario A González; Theresa Henry; Matthew Howard; Jason Kamm; Steven Laurenz; Ryan MacKenzie; Richard Mannion; Patrick K Noonan; Terrance Ocheltree; Umesh Pai; Richard P Poska; Michael L Putnam; Ramani R Raghavan; Colleen Ruegger; Eric Sánchez; Vinod P Shah; Zezhi Jesse Shao; Russell Somma; Vijay Tammara; Avinash G Thombre; Bruce Thompson; Robert J Timko; Satyam Upadrashta; Sivakumar Vaithiyalingam
Journal:  AAPS PharmSciTech       Date:  2014-03-01       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.